Loading clinical trials...
Loading clinical trials...
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C wh...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amgen
Collaborators
NCT07578090 · Hypertension, Cardiovascular Disease, and more
NCT06451770 · Hypercholesterolemia, Hypertriglyceridemia, and more
NCT07473960 · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
NCT06062394 · Hypertension, Hyperlipidemias
NCT07230730 · Hyperlipidemia
Research Site
Birmingham, Alabama
Research Site
Tucson, Arizona
Research Site
Malvern, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions